Targeting histone modifications in colorectal cancer: therapeutic potential of epigenetic modifiers on acetylation, methylation and phosphorylation
Epigenetic modifiers targeting histone acetylation, methylation, and phosphorylation show significant preclinical promise in CRC. Combination strategies and novel degraders offer pathways to overcome resistance, including PROTACs targeting KDM3A/B that eliminate cancer stem cells via Wnt/β-catenin inhibition.